Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $68.44, but opened at $63.72. Zealand Pharma A/S shares last traded at $63.72, with a volume of 284 shares traded.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Finally, Zacks Research raised shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Six equities research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Stock Down 1.5%

The firm has a 50-day moving average of $76.47 and a two-hundred day moving average of $68.72. The stock has a market capitalization of $4.68 billion, a price-to-earnings ratio of 4.74 and a beta of 0.74. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.21. The company had revenue of $7.76 million for the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. As a group, sell-side analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.